Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

被引:216
作者
Sung, BJ
Hwang, KY
Jeon, YH
Lee, JI
Heo, YS
Kim, JH
Moon, J
Yoon, JM
Hyun, YL
Kim, E
Eum, SJ
Park, SY
Lee, JO
Lee, TG
Ro, S
Cho, JM
机构
[1] CrystalGenom Inc, Div Drug Discovery, Taejon 305390, South Korea
[2] Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan
[3] Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea
关键词
D O I
10.1038/nature01914
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP(1-3). As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction(4-7). Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available(8,9). Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 23 条
[11]   CRYSTAL-STRUCTURE OF A TFIIB-TBP-TATA-ELEMENT TERNARY COMPLEX [J].
NIKOLOV, DB ;
CHEN, H ;
HALAY, ED ;
USHEVA, AA ;
HISATAKE, K ;
LEE, DK ;
ROEDER, RG ;
BURLEY, SK .
NATURE, 1995, 377 (6545) :119-128
[12]  
Orme M W, 2002, [No title captured], Patent No. [WO 0236593, 0236593]
[13]   Processing of X-ray diffraction data collected in oscillation mode [J].
Otwinowski, Z ;
Minor, W .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :307-326
[14]   Phosphodiesterase 5 inhibitors: Current status and potential applications [J].
Rotella, DP .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :674-682
[15]   PDE5 is converted to an activated state upon cGMP binding to the GAF A domain [J].
Rybalkin, SD ;
Rybalkina, IG ;
Shimizu-Albergine, M ;
Tang, XB ;
Beavo, JA .
EMBO JOURNAL, 2003, 22 (03) :469-478
[16]  
Sekhar K.R., 1996, Phosphodiesterase Inhibitors, P135
[17]   Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions [J].
Soderling, SH ;
Beavo, JA .
CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (02) :174-179
[18]   Automated MAD and MIR structure solution [J].
Terwilliger, TC ;
Berendzen, J .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1999, 55 :849-861
[19]   Maximum-likelihood density modification [J].
Terwilliger, TC .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2000, 56 :965-972
[20]   Phosphodiesterase isozymes - Molecular targets for novel antiasthma agents [J].
Torphy, TJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (02) :351-370